New clotting factor put to the test against standard therapies

NCT ID NCT06579144

Recruiting now Knowledge-focused Sponsor: Swedish Orphan Biovitrum Source: ClinicalTrials.gov ↗

First seen Jan 04, 2026 · Last updated May 14, 2026 · Updated 19 times

Summary

This study compares a new clotting factor medicine (efanesoctocog alfa) with two existing ones in adults with severe hemophilia A. About 24 men aged 18-65 will receive a single dose of their current treatment and then a single dose of the new medicine. The main goal is to see how long each medicine stays active in the blood, which could help improve treatment schedules.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Sobi Investigational Site
RECRUITING

Sofia, Bulgaria

Contact
Sobi Investigational Site
RECRUITING

Oldenburg, Germany

Contact
Sobi Investigational Site
RECRUITING

Milan, Italy

Contact
Sobi Investigational Site
NOT_YET_RECRUITING

Naples, Italy

Contact
Sobi Investigational Site
RECRUITING

A Coruña, Spain

Contact
Sobi Investigational Site
RECRUITING

Valencia, Spain

Contact
Sobi Investigational Site
RECRUITING

Zaragoza, Spain

Contact
Sobi Investigational site
RECRUITING

Frankfurt, Germany

Contact

Conditions

Explore the condition pages connected to this study.

HEMOPHILIA A